A Study of Revumenib and Mezigdomide in People With Leukemia

NCT07356154 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Acute Leukemia
Relapse Leukemia
Refractory Leukemia
Refractory Acute Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia

Interventions

DRUG: Revumenib
DRUG: Mezigdomide

Sponsor

Memorial Sloan Kettering Cancer Center